Sun Pharmaceutical Industries Limited has entered into a definitive agreement to acquire all outstanding shares of Organon & Co. in an all-cash transaction valued at $11.75 billion. Under the terms, Sun Pharma will pay US$14.00 per share, marking one of the largest acquisitions by an Indian pharmaceutical company. The transaction has already received approval from the boards of both companies and remains subject to customary regulatory clearances and approval from Organon’s shareholders.
Strong Presence in Women’s Health and Biosimilars
Organon, which was spun off from Merck & Co. in 2021, has built a strong global presence across 140 countries. The company is widely recognised for its leadership in women’s health, supported by a portfolio of more than 70 products spanning women’s health, biosimilars, and general medicines.
Additionally, Organon operates six manufacturing facilities across the European Union and emerging markets, reinforcing its global scale and supply capabilities. Its key markets include the United States, Europe, China, Canada, and Brazil.
Strategic Fit: Strengthening Innovation and Generics Portfolio
The acquisition aligns closely with Sun Pharma’s strategy to expand its Innovative Medicines business while reinforcing its leadership in established brands and branded generics. At the same time, the deal enables Sun Pharma to enter the biosimilars segment as a top-10 global player. By integrating Organon’s diversified portfolio and global footprint, Sun Pharma aims to unlock long-term value and strengthen its competitive positioning across multiple therapeutic segments.
Post-Acquisition Scale and Market Positioning
Following the completion of the transaction, the combined entity is expected to achieve significant scale and strategic advantages:
*Rank among the top 25 global pharmaceutical companies with combined revenues of approximately US$12.4 billion
*Strengthen its position in established brands and branded generics
*Increase contribution from innovative medicines to around 27% of revenues
*Emerge as a top 3 player in global women’s health
*Become the 7th largest biosimilar company worldwide
*Expand presence to 150 countries, with 18 key markets generating over US$100 million each
The combined company is expected to significantly enhance its EBITDA and cash flow, supporting deleveraging despite a post-transaction net debt/EBITDA ratio of 2.3x.
Leadership Commentary
Dilip Shanghvi, Executive Chairman of Sun Pharma, emphasised that the acquisition represents a major step in advancing the company’s vision of expanding global access to healthcare. He noted that Organon’s portfolio and capabilities complement Sun Pharma’s strengths and will help build a more diversified and resilient business.
Managing Director Kirti Ganorkar highlighted that the deal will strengthen Sun Pharma’s position as a global partner for product launches and acquisitions. He added that the company will prioritise smooth integration, business continuity, and long-term value creation, while also leveraging potential revenue synergies.
Carrie Cox, Executive Chair of Organon, stated that the all-cash transaction delivers immediate and compelling value to shareholders. She also expressed confidence in Sun Pharma’s ability to support Organon’s global operations and advance its mission of improving access to essential medicines.
Creating a Stronger Global Healthcare Platform
As per the press release, the acquisition marks a transformative move for Sun Pharma. By combining innovation, scale, and global reach, the company is well-positioned to accelerate growth across key therapeutic areas, including women’s health and biosimilars, while reinforcing its role in the global pharmaceutical landscape.
